Nathan A Berger
Overview
Explore the profile of Nathan A Berger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
124
Citations
3094
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Norooz M, Safavi-Naini S, Jamshidi P, Sadeghi A, Tabesh M, Abolhasani M, et al.
Health Sci Rep
. 2025 Feb;
8(2):e70431.
PMID: 39980832
Background: Weight regain after surgery is linked to an increased risk of relapse for obesity-related comorbidities, such as type 2 diabetes mellitus (T2DM). This study aims to explore how exercise...
2.
Sun X, Chen Z, Cooper G, Berger N, Coulton C, Li L
Fam Med Community Health
. 2024 Nov;
12(Suppl 2).
PMID: 39574362
Objective: Neighbourhood deprivation increases the risk of colorectal neoplasia and contributes to racial disparities observed in this disease. Developing race-specific advanced colorectal neoplasia (ACN) prediction models that include neighbourhood socioeconomic...
3.
Wang W, Volkow N, Wang Q, Berger N, Davis P, Kaelber D, et al.
JAMA Netw Open
. 2024 Sep;
7(9):e2435247.
PMID: 39320894
No abstract available.
4.
Schmitz K, Brown J, Irwin M, Robien K, Scott J, Berger N, et al.
J Natl Cancer Inst
. 2024 Aug;
117(1):9-19.
PMID: 39118255
Chemotherapy treatment-related side effects are common and increase the risk of suboptimal outcomes. Exercise interventions during cancer treatment improve self-reported physical functioning, fatigue, anxiety, and depression, but it is unclear...
5.
Wang W, Volkow N, Berger N, Davis P, Kaelber D, Xu R
Ann Intern Med
. 2024 Jul;
177(8):1016-1027.
PMID: 39074369
Background: Reports of reduced desire to smoke in patients treated with semaglutide, a glucagon-like peptide receptor agonist (GLP-1RA) medication for type 2 diabetes mellitus (T2DM) and obesity, have raised interest...
6.
Tabernacki T, Wang L, Kaelber D, Xu R, Berger N
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001440
Lung cancer (LC) is the second most common cancer and the leading cause of cancer deaths in the U.S. Insulin therapy, a key treatment for managing Type 2 Diabetes Mellitus...
7.
Wang L, Xu R, Kaelber D, Berger N
JAMA Netw Open
. 2024 Jul;
7(7):e2421305.
PMID: 38967919
Importance: Thirteen human malignant neoplasms have been identified as obesity-associated cancers (OACs), ie, the presence of excess body fat is associated with increased risk of developing cancer and worse prognosis...
8.
Wang W, Volkow N, Berger N, Davis P, Kaelber D, Xu R
Nat Commun
. 2024 Jun;
15(1):5177.
PMID: 38890337
No abstract available.
9.
Wang W, Volkow N, Berger N, Davis P, Kaelber D, Xu R
Nat Commun
. 2024 May;
15(1):4548.
PMID: 38806481
Alcohol use disorders are among the top causes of the global burden of disease, yet therapeutic interventions are limited. Reduced desire to drink in patients treated with semaglutide has raised...
10.
Wang L, Berger N, Kaelber D, Xu R
Gastroenterology
. 2024 May;
167(4):689-703.
PMID: 38692395
Background & Aims: Hepatocellular carcinoma (HCC) is a leading cause of cancer death. HCC is preventable with about 70% of HCC attributable to modifiable risk factors. Glucagon-like peptide-1 receptor agonists...